Vera Therapeutics, Inc. (VERA) Stock Price & Analysis
Vera Therapeutics, Inc. (VERA) fell 2.48% to USD 35.45 as of July 25, 2026 at 03:52 UTC, according to Nexqual real-time market data.
VERA last closed at USD 36.35; the session ranged USD 35.41–36.71 on volume of 786,074 shares. Market capitalization is $2.54B, with a 52-week range of USD 19.07–56.05 (NGM). Source: Nexqual, July 25, 2026 at 03:52 UTC.
Key Statistics (as of July 25, 2026 at 03:52 UTC)
| Price | USD 35.45 |
|---|---|
| Change | ▼ 2.48% (down) |
| Previous Close | USD 36.35 |
| Open | USD 36.71 |
| Day Range | USD 35.41 – 36.71 |
| 52-Week Range | USD 19.07 – 56.05 |
| Volume | 786,074 shares |
| Market Cap | $2.54B |
| Exchange | NGM |
Technical Analysis (VERA)
Nexqual's technical model rates VERA "SELL" based on 1 bullish and 5 bearish signals across 125 daily candles, as of July 25, 2026 at 03:52 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 40.47 (neutral) |
| vs SMA50 | Below (USD 37.11) |
| MACD | -0.38 (negative) |
Analyst Ratings (VERA)
Wall Street analysts rate VERA "Strong Buy" based on 14 analysts, with a mean price target of USD 81.79 (range USD 43–125), per Nexqual as of July 25, 2026 at 03:52 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 14 |
| Mean Target | USD 81.79 |
| High Target | USD 125 |
| Low Target | USD 43 |
| Buy / Hold / Sell | 13 / 1 / 0 |
Earnings (VERA)
| Next Earnings Date | 2026-08-04 |
|---|---|
| EPS Estimate | USD -1.59 |
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -1.69 vs est -1.37 ▼ miss |
| 2025-12-31 | USD -1.39 vs est -1.27 ▼ miss |
| 2025-09-30 | USD -1.26 vs est -1.13 ▼ miss |
| 2025-06-30 | USD -1.2 vs est -0.62 ▼ miss |
Source: Nexqual, July 25, 2026 at 03:52 UTC.
Financials & Fundamentals (VERA)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -71.32% |
| Debt / Equity | 15.39 |
| Current Ratio | 13.64 |
| Total Cash | $596.76M |
| Total Debt | $76.89M |
| Free Cash Flow | $-179.42M |
Source: Nexqual, July 25, 2026 at 03:52 UTC.
Financial Health Score (VERA)
Nexqual rates Vera Therapeutics, Inc.'s overall financial health "Mixed" across five dimensions, as of July 25, 2026 at 03:52 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $597M cash vs $77M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -$293M |
| Efficiency | Critical — ROE -71%, ROA -38.9% |
Ownership (VERA)
| Insider Ownership | +0.78% |
|---|---|
| Institutional Ownership | +110.70% |
| Shares Outstanding | 71.78M |
| Float | 51.95M |
| Short % of Float | +21.45% |
Source: Nexqual, July 25, 2026 at 03:52 UTC.
Leadership (VERA)
Vera Therapeutics, Inc. is led by Marshall W. Fordyce (age 50), Founder, President, CEO & Director, per Nexqual as of July 25, 2026 at 03:52 UTC.
| Founder, President, CEO & Director | Marshall W. Fordyce (age 50) |
|---|---|
| Chief Financial Officer | Sean P. Grant (age 40) |
| Vice President of Corporate Communications | Debra Charlesworth |
| Vice President of Marketing | Emma Haywood |
Major Backers & Investors (VERA)
Notable institutional backers of Vera Therapeutics, Inc. include Avoro Capital Advisors LLC, Price (T.Rowe) Associates Inc, Deep Track Capital, Lp, according to Nexqual as of July 25, 2026 at 03:52 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Avoro Capital Advisors LLC | 8.2% |
| Price (T.Rowe) Associates Inc | 6.37% |
| Deep Track Capital, Lp | 5.72% |
| Deerfield Management Company, L.P | 5.19% |
| Kynam Capital Management, LP | 4.73% |
| T. Rowe Price | 4.24% |
| Sofinnova Investments, Inc. | 3.89% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 9.15% |
| State Street | 8.37% |
| Vanguard Group | 7.39% |
Source: Nexqual, July 25, 2026 at 03:52 UTC.
From Vera Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-02-26)
Key Strengths & Strategy (as disclosed to the SEC)
- Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with immunological diseases.
- The company offers atacicept, a fully humanized TACI-Fc fusion protein that binds B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL), which is self-administered at home as a subcutaneous injection being evaluated for the treatment of immunoglobulin A nephropathy (IgAN) and other autoimmune kidney diseases.
- It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections that has completed phase 2 clinical trial; and VT-109, a novel BAFF/APRIL dual-inhibitor B cell maturation antigen (BCMA) molecule to treat B cell mediated autoimmune diseases.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| JANX | Janux Therapeutics, Inc. | USD 15.33 | ▼ 1.86% |
| EWTX | Edgewise Therapeutics, Inc. | USD 40.84 | ▲ 6.55% |
| KYMR | Kymera Therapeutics, Inc. | USD 110.57 | ▲ 0.21% |
| NUVL | Nuvalent, Inc. | USD 123.96 | ▲ 0% |
| VRDN | Viridian Therapeutics, Inc. | USD 19.27 | ▲ 0.52% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 03:52 UTC. This page is informational and not investment advice.